7th Edition Clinical Trials in Canada

$499.00

SKU: PHP09422 Category:

Description

Report Code: PHP09422. October, 2009. Toronto, ON

ARTICLE I

A Health Research Roadmap: Creating Innovative Research for Better Health and Healthcare

Alain Beaudet, MD., Ph.D.
President
Canadian Institutes of Health Research

ARTICLE II

National Initiatives and Innovation in REB Review in Canada

Ron Heslegrave Ph.D.
Chair, Research Ethics Board
University Health Network
Ontario Cancer Research Ethics Board

ARTICLE III

Attracting and Retaining Clinical Trials in Canada

John Akitt
President and Co-founder
Trial Management Group (TMG)

Marie-Claude Gauthier, B.Sc.
Director, Clinical Research
Pfizer Canada Inc.

Dr. Catriona McMahon, BSc., MBChB, FRCA (UK), MFPM (UK)
Vice President, Medical Affairs
AstraZeneca Canada Inc.

Nestor Nituch
Unit Director, Regional Clinical Operations
Bristol-Myers Squibb Canada

ARTICLE IV

Independent Ethics Review: Challenges and Opportunities

Jack Corman
President
Institutional Review Board Services

ARTICLE V

Finding A Balance Between Innovation and Participant Protection

Richard Sugarman
Chair
SickKids REB

ARTICLE VI

Completing the Drug Development Circle: Post-Marketing/Phase IV and Observational Clinical Trials

Dr. John S. Sampalis
Associate Professor of Surgery, Epidemiology & Biostatistics, McGill University, University of Montreal & Laval University; President
JSS Medical Research Inc.

ARTICLE VII

Montreal Roundtable Summary: How Sponsors, Institutions/Pls and CROs Can Smooth Out and Speed Up the Negotiation of Clinical Trial Contracts in Canada

Marie-Luce Fortier, LL.L., LL.B.
Lawyer
Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM)

Alaine C. Grand
Legal Counsel
AstraZeneca Canada Inc.

Michelle Moldofsky, LLB, LLM
Policy & Legal Advisory, Office of Research Administration
St. Michael’s Hospital

Maria Rossin, BA, LLB, JD
Research Counsel
The Samuel Lunenfeld Research Institute

ARTICLE VIII

Clinical Trials Competitiveness

Mark Ferdinand
Vice President, Policy, Research, Regulatory & Scientific Affairs
Canada’s Research-Based Pharmaceutical Companies (Rx&D)

ARTICLE IX

Privacy Issues in the Pharmaceutical Context: Legal, Ethical & IT Perspective

Khaled El Emam
Associate Professor, Canada Research Chair in Electronic Health Information
University of Ottawa

Patricia Kosseim
Chief GE3 LS Officer
Genome Canada

ARTICLE X

Motivating Investigators in Specialized Clinical Research

Pierre Gervais, B.Pharm., MSc
Director, Business Development, Q&T Research Outaouais; Ex-president, Quebec Association of Clinical Research (AQRC); President
Q&T Research – Sherbrooke

ARTICLE XI

Biotech and Big Pharma: Strategic, Innovative Partnerships in R&D

Matthew J. Carlyle
Chief Financial Officer
Allon Therapeutics, Inc.

ARTICLE XII

Regulatory Transparency: Issues that Can Impact Our Competitive Effectiveness in the Conduct of Multicentre International Clinical Trials

Anne Tomalin, BA, BSc, RAC
President
CanReg Inc.

ARTICLE XIII

Canada: Your Location of Choice for Clinical Trials

Brad Millson, BSc., MBS
Investment Advisor, Life Science Practice
Foreign Affairs and International Trade Canada